Cyanoindole LSD1 Inhibitors Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for LSD1-mediated diseases lack effective novel small molecules that can inhibit LSD1 activity, particularly for both irreversible and reversible inhibitors, which are necessary for managing excessive LSD1 activity associated with various cancers and disorders.
Innovation Solution
Development of cyano-substituted indole compounds, including their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, and solvates, which are designed to target LSD1 for therapeutic use in treating LSD1-mediated diseases, such as various leukemias, lymphomas, and cancers, either alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MAO inhibitors are used to target LSD1 through irreversible interaction of FAD, then LSD1 activity is inhibited, but the approach lacks selectivity and may cause off-target effects
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target the catalytic domain of LSD1 with precise molecular features. The compounds are engineered to interact with specific amino acid residues in the LSD1 active site, ensuring localized and selective inhibition without affecting other enzymes like MAO, thereby resolving the contradiction between efficacy and selectivity
Solution Approach 2:
The patent employs parameter changes by optimizing the chemical structure of indole compounds with specific substituents (R1-R6 groups) to fine-tune their binding affinity and selectivity for LSD1. By adjusting parameters such as molecular weight, hydrophobicity, and electronic properties through systematic structural modifications, the compounds achieve potent and selective LSD1 inhibition while avoiding off-target effects
2Adaptability or versatility
If reversible inhibitors of LSD1 are developed, then therapeutic options are expanded, but the potency and stability of reversible binding may be insufficient compared to irreversible inhibitors
Solution Approach 1:
The patent applies dynamics by designing reversible inhibitors with optimized binding kinetics. The compounds are engineered to achieve slow off-rates through multiple weak interactions with the LSD1 active site, including hydrogen bonds, hydrophobic interactions, and pi-stacking. This dynamic binding approach provides sufficient potency and stability for therapeutic effect while maintaining reversibility, allowing the enzyme to recover function after drug clearance
Solution Approach 2:
The patent employs composite materials by creating indole core structures with multiple functional groups that work synergistically. The R1-R6 substituents are designed to form a network of interactions with LSD1 residues, combining different bonding modes (hydrogen bonding, hydrophobic effects, electrostatic interactions) to achieve high potency reversible inhibition, effectively creating a composite molecular structure that overcomes the limitations of simple reversible binders
Data Source
AI summary
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders:wherein R1, R2, R3, R4, and R5 are as defined herein.